Plasma urea cycle metabolite levels and the risk of moyamoya disease
Background and purposeUrea cycle metabolites are expected to be the biomarkers for cerebrovascular diseases. However, the effects of circulating urea cycle metabolites on the risk of MMD and its subcategories remain unclear. The aim of this study was to prospectively investigate the association betw...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2023.1163733/full |
| _version_ | 1797783951652159488 |
|---|---|
| author | Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Peicong Ge Peicong Ge Peicong Ge Peicong Ge Peicong Ge Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Wei Liu Wei Liu Wei Liu Wei Liu Wei Liu Qian Zhang Qian Zhang Qian Zhang Qian Zhang Qian Zhang Xun Ye Xun Ye Xun Ye Xun Ye Xun Ye Xingju Liu Xingju Liu Xingju Liu Xingju Liu Xingju Liu Rong Wang Rong Wang Rong Wang Rong Wang Rong Wang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang |
| author_facet | Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Peicong Ge Peicong Ge Peicong Ge Peicong Ge Peicong Ge Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Wei Liu Wei Liu Wei Liu Wei Liu Wei Liu Qian Zhang Qian Zhang Qian Zhang Qian Zhang Qian Zhang Xun Ye Xun Ye Xun Ye Xun Ye Xun Ye Xingju Liu Xingju Liu Xingju Liu Xingju Liu Xingju Liu Rong Wang Rong Wang Rong Wang Rong Wang Rong Wang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang |
| author_sort | Xiaofan Yu |
| collection | DOAJ |
| description | Background and purposeUrea cycle metabolites are expected to be the biomarkers for cerebrovascular diseases. However, the effects of circulating urea cycle metabolites on the risk of MMD and its subcategories remain unclear. The aim of this study was to prospectively investigate the association between plasma urea cycle metabolites and the risk of MMD and its subcategories.MethodsWe measured plasma urea cycle metabolite levels for 360 adult MMD patients and 89 matched healthy controls. Clinical and laboratory characteristics were obtained from the medical record. The study was conducted from July 2020 to December 2021.ResultsAfter multivariate adjustment, the risk of MMD increased with each increment in ornithine level (per natural log [ornithine] increment: OR, 3.893; 95% CI, 1.366–11.090). The risk of MMD decreased with each increment in arginine level (per natural log [arginine] increment: OR, 0.109; 95% CI, 0.028–0.427), urea level (per natural log [urea] increment: OR, 0.261; 95% CI, 0.072–0.940), and global arginine bioavailability ratio (GABR) level (per natural log [GABR] increment: OR, 0.189; 95% CI, 0.074–0.484). The addition of plasma arginine (integrated discrimination improvement: 1.76%, p = 0.021) or GABR (integrated discrimination improvement: 1.76%, p = 0.004) to conventional risk factors significantly improved the risk reclassification for MMD.ConclusionPlasma ornithine levels are positively associated with the risk of MMD. By contrast, the levels of arginine, urea, and GABR are inversely related to the risk of MMD. Plasma urea cycle metabolites might be potential biomarkers for the risk of MMD. |
| first_indexed | 2024-03-13T00:34:10Z |
| format | Article |
| id | doaj.art-b08e137ca5244ff6b744e0908c2e33c5 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-03-13T00:34:10Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-b08e137ca5244ff6b744e0908c2e33c52023-07-10T08:35:08ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2023-07-011710.3389/fnins.2023.11637331163733Plasma urea cycle metabolite levels and the risk of moyamoya diseaseXiaofan Yu0Xiaofan Yu1Xiaofan Yu2Xiaofan Yu3Xiaofan Yu4Peicong Ge5Peicong Ge6Peicong Ge7Peicong Ge8Peicong Ge9Yuanren Zhai10Yuanren Zhai11Yuanren Zhai12Yuanren Zhai13Yuanren Zhai14Wei Liu15Wei Liu16Wei Liu17Wei Liu18Wei Liu19Qian Zhang20Qian Zhang21Qian Zhang22Qian Zhang23Qian Zhang24Xun Ye25Xun Ye26Xun Ye27Xun Ye28Xun Ye29Xingju Liu30Xingju Liu31Xingju Liu32Xingju Liu33Xingju Liu34Rong Wang35Rong Wang36Rong Wang37Rong Wang38Rong Wang39Yan Zhang40Yan Zhang41Yan Zhang42Yan Zhang43Yan Zhang44Jizong Zhao45Jizong Zhao46Jizong Zhao47Jizong Zhao48Jizong Zhao49Jizong Zhao50Dong Zhang51Dong Zhang52Dong Zhang53Dong Zhang54Dong Zhang55Dong Zhang56Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaSavaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaBeijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, Beijing, ChinaDepartment of Neurosurgery, Beijing Hospital, Beijing, ChinaBackground and purposeUrea cycle metabolites are expected to be the biomarkers for cerebrovascular diseases. However, the effects of circulating urea cycle metabolites on the risk of MMD and its subcategories remain unclear. The aim of this study was to prospectively investigate the association between plasma urea cycle metabolites and the risk of MMD and its subcategories.MethodsWe measured plasma urea cycle metabolite levels for 360 adult MMD patients and 89 matched healthy controls. Clinical and laboratory characteristics were obtained from the medical record. The study was conducted from July 2020 to December 2021.ResultsAfter multivariate adjustment, the risk of MMD increased with each increment in ornithine level (per natural log [ornithine] increment: OR, 3.893; 95% CI, 1.366–11.090). The risk of MMD decreased with each increment in arginine level (per natural log [arginine] increment: OR, 0.109; 95% CI, 0.028–0.427), urea level (per natural log [urea] increment: OR, 0.261; 95% CI, 0.072–0.940), and global arginine bioavailability ratio (GABR) level (per natural log [GABR] increment: OR, 0.189; 95% CI, 0.074–0.484). The addition of plasma arginine (integrated discrimination improvement: 1.76%, p = 0.021) or GABR (integrated discrimination improvement: 1.76%, p = 0.004) to conventional risk factors significantly improved the risk reclassification for MMD.ConclusionPlasma ornithine levels are positively associated with the risk of MMD. By contrast, the levels of arginine, urea, and GABR are inversely related to the risk of MMD. Plasma urea cycle metabolites might be potential biomarkers for the risk of MMD.https://www.frontiersin.org/articles/10.3389/fnins.2023.1163733/fullmoyamoya diseaseurea cycleornithineargininerisk factors |
| spellingShingle | Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Xiaofan Yu Peicong Ge Peicong Ge Peicong Ge Peicong Ge Peicong Ge Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Yuanren Zhai Wei Liu Wei Liu Wei Liu Wei Liu Wei Liu Qian Zhang Qian Zhang Qian Zhang Qian Zhang Qian Zhang Xun Ye Xun Ye Xun Ye Xun Ye Xun Ye Xingju Liu Xingju Liu Xingju Liu Xingju Liu Xingju Liu Rong Wang Rong Wang Rong Wang Rong Wang Rong Wang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Yan Zhang Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Jizong Zhao Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang Dong Zhang Plasma urea cycle metabolite levels and the risk of moyamoya disease Frontiers in Neuroscience moyamoya disease urea cycle ornithine arginine risk factors |
| title | Plasma urea cycle metabolite levels and the risk of moyamoya disease |
| title_full | Plasma urea cycle metabolite levels and the risk of moyamoya disease |
| title_fullStr | Plasma urea cycle metabolite levels and the risk of moyamoya disease |
| title_full_unstemmed | Plasma urea cycle metabolite levels and the risk of moyamoya disease |
| title_short | Plasma urea cycle metabolite levels and the risk of moyamoya disease |
| title_sort | plasma urea cycle metabolite levels and the risk of moyamoya disease |
| topic | moyamoya disease urea cycle ornithine arginine risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2023.1163733/full |
| work_keys_str_mv | AT xiaofanyu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xiaofanyu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xiaofanyu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xiaofanyu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xiaofanyu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT peicongge plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT peicongge plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT peicongge plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT peicongge plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT peicongge plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yuanrenzhai plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yuanrenzhai plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yuanrenzhai plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yuanrenzhai plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yuanrenzhai plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT weiliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT weiliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT weiliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT weiliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT weiliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT qianzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT qianzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT qianzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT qianzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT qianzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xunye plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xunye plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xunye plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xunye plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xunye plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xingjuliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xingjuliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xingjuliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xingjuliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT xingjuliu plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT rongwang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT rongwang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT rongwang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT rongwang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT rongwang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yanzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yanzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yanzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yanzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT yanzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT jizongzhao plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease AT dongzhang plasmaureacyclemetabolitelevelsandtheriskofmoyamoyadisease |